Brief: Daré Bioscience Announces Achievement Of First Commercial Milestone Under License Agreement For XACIATIO (Clindamycin Phosphate) Vaginal Gel

Dare Bioscience

16/10/2023 14:21

Oct 16 (Reuters) - Dare Bioscience Inc  DARE.O :
    * DARÉ BIOSCIENCE ANNOUNCES ACHIEVEMENT OF FIRST COMMERCIAL
MILESTONE UNDER LICENSE AGREEMENT FOR XACIATO™ (CLINDAMYCIN
PHOSPHATE) VAGINAL GEL, 2%, FDA-APPROVED TREATMENT FOR BACTERIAL
VAGINOSIS IN FEMALES 12 YEARS OR OLDER

Source text for Eikon:  ID:nGNX9BCQwh 
Further company coverage:  DARE.O 

 ((Reuters.Briefs@thomsonreuters.com;))